Eve™ CCHD Newborn Screening Application
Eve combines Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry with step-by-step instructions to assist clinicians in screening for Critical Congenital Heart Disease (CCHD)
Home / Eve
Eve application is available on the Rad-97™ and Radical-7® Pulse Co-Oximeters®
Eve™ CCHD Newborn Screening Application
Eve combines Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry with step-by-step instructions to assist clinicians in screening for Critical Congenital Heart Disease (CCHD)
Eve simplifies the CCHD screening process, per an established protocol1, by providing visual instructions, animations, an automatic synchronization algorithm, and a detailed, easy-to-interpret display of screening results
Animations provide visual guidance to assist clinicians through the screening process
An automatic synchronization algorithm, with an easy-to-interpret results screen, may reduce calculation errors
Settings allow clinicians to incorporate perfusion index (Pi) measurement, which may increase sensitivity to detection of CCHD2
EMR integration via Masimo Patient SafetyNet™* or Iris Gateway™ facilitates workflow and may help reduce reporting errors
Step-By-Step Instruction Improves Consistency and Workflow Efficiency
CCHD Screening with Masimo SET® Pulse Oximetry
Improved Critical Congenital Heart Disease Screening Sensitivity vs. Clinical Assessment Alone3
- In a study of 39,821 infants, CCHD screening sensitivity increased from 63% with physical exam alone to 83% with physical exam and Masimo SET® pulse oximetry.2
- In a study of 122,738 infants, CCHD screening sensitivity increased from 77% to 93% with the combined use of Masimo SET® and clinical assessment.3
Learn More About CCHD Screening with Masimo SET®
References:
- 1.
Kemper AR, Mahle WT, Martin GR, Cooley WC, Kumar P, Morrow WR, Kelm K, Pearson GD, Glidewell J, Grosse SD, Howell, RR. Strategies for Implementing Screening for Critical Congenital Heart Disease. Pediatrics. 2011 Oct; 128(5):1259-67.
- 2.
de-Wahl Granelli A et al. BMJ. 2009;338:a3037.
- 3.
Zhao et al. Lancet. 2014 Aug 30;384(9945):747-54.
* The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.
RESOURCES
Eve has obtained CE Marking. Not available in the U.S. Rad-97 with Eve is not licensed for sale in Canada.
For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.
© 2019 Masimo. All Rights Reserved.